Equities Analysts Offer Predictions for CRL Q2 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) - Stock analysts at Zacks Research increased their Q2 2025 earnings estimates for Charles River Laboratories International in a research note issued on Monday, June 2nd. Zacks Research analyst R. Department now forecasts that the medical research company will earn $2.49 per share for the quarter, up from their previous estimate of $2.46. The consensus estimate for Charles River Laboratories International's current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International's Q3 2025 earnings at $2.35 EPS, Q4 2025 earnings at $2.35 EPS, Q2 2026 earnings at $2.69 EPS, Q3 2026 earnings at $2.48 EPS, Q4 2026 earnings at $2.46 EPS, Q1 2027 earnings at $2.88 EPS and FY2027 earnings at $10.98 EPS.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its earnings results on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping the consensus estimate of $2.06 by $0.28. The company had revenue of $984.17 million for the quarter, compared to analysts' expectations of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The business's revenue for the quarter was down 2.7% on a year-over-year basis. During the same period last year, the firm earned $2.27 earnings per share.

Other equities analysts have also issued research reports about the company. Redburn Atlantic upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and decreased their price target for the company from $188.00 to $182.00 in a research note on Friday, May 23rd. Barclays upped their price target on Charles River Laboratories International from $145.00 to $155.00 and gave the company an "equal weight" rating in a research report on Thursday, May 8th. Robert W. Baird upped their price target on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the company a "neutral" rating in a research report on Thursday, May 8th. JPMorgan Chase & Co. reduced their price objective on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating for the company in a research report on Thursday, February 20th. Finally, Morgan Stanley dropped their target price on shares of Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $171.85.

Charles River Laboratories International Price Performance

Shares of NYSE CRL traded down $1.88 during mid-day trading on Wednesday, reaching $141.34. The company had a trading volume of 728,930 shares, compared to its average volume of 994,050. The business's 50-day simple moving average is $127.93 and its 200 day simple moving average is $159.55. The firm has a market cap of $6.94 billion, a price-to-earnings ratio of 942.25, a PEG ratio of 4.54 and a beta of 1.48. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. Charles River Laboratories International has a one year low of $91.86 and a one year high of $254.15.

Insider Activity

In other news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president now owns 19,513 shares in the company, valued at $2,837,385.33. This represents a 2.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Corporate insiders own 1.30% of the company's stock.

Institutional Investors Weigh In On Charles River Laboratories International

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Robeco Institutional Asset Management B.V. grew its holdings in shares of Charles River Laboratories International by 3.0% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 4,354 shares of the medical research company's stock valued at $804,000 after acquiring an additional 126 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its position in Charles River Laboratories International by 24.5% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,463 shares of the medical research company's stock worth $455,000 after purchasing an additional 485 shares during the last quarter. Boston Trust Walden Corp increased its position in shares of Charles River Laboratories International by 4.3% during the 4th quarter. Boston Trust Walden Corp now owns 204,483 shares of the medical research company's stock valued at $37,748,000 after purchasing an additional 8,338 shares during the last quarter. Trust Point Inc. bought a new stake in shares of Charles River Laboratories International during the 4th quarter worth $378,000. Finally, E. Ohman J or Asset Management AB boosted its holdings in shares of Charles River Laboratories International by 225.0% in the 4th quarter. E. Ohman J or Asset Management AB now owns 2,600 shares of the medical research company's stock worth $480,000 after buying an additional 1,800 shares during the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).